A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
Trial details
- Registry ID
- NCT07812090
- Drugs studied
- Anti-VEGF, Oral BGE-102
TrialRedline tracks 4 clinical trials sponsored by BioAge Labs, Inc.: 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaNCT07812090 | Anti-VEGF, Oral BGE-102 | Recruiting | 2027-11Estimated |
| A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsNCT07656727 | Oral BGE-102 | Active not recruiting | 2026-11-30Estimated |
| Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and OverNCT06515418 | Oral Azelaprag (BGE-105), Tirzepatide | Terminated | 2025-02-06Actual |
| Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory FailureNCT04705597 | BGE-175 | Terminated | 2022-04-20Actual |
Names as written in the registry records.
Before: Recruiting. After: Active not recruiting.